Medicinal Chemistry Consultant for Drug Discovery, Preclinical Pharmacology and ADME

Technical Consultant #1513

Pharmaceutical drug discovery process and implementation.
Drug discovery and medicinal chemistry.
Preclinical pharmacology, ADME (absorption, distribution, metabolism, and excretion of drugs) and pharmaceutical toxicology and safety.
Pharmaceutical drugs for anti-infectives, anti-virals, oncology and immunology.
Pharmaceutical drugs for cardiovascular and metabolic disease.
Pharmaceutical drugs for diabetes, obesity, aging and frailty.
Due diligence assessments, including intellectual property.

Undisclosed Company, President 2007 - Present

Drug discovery consultant with clients ranging from large to small pharmaceutical companies having portfolios in oncology, metabolic diseases, anti-virals, anti-bacterials and ocular diseases.
Consult on strategy and tactics in drug discovery including medicinal chemistry, preclinical pharmacology, ADME, pharmaceutics and drug safety.
Design and implementation of drug discovery programs and strategies to assure the expeditious achievement of drug discovery goals.

Undisclosed Company, 1981 - 2007

Executive Director Discovery, Chemistry, 2002 - 2007

Experienced across a wide array of peripheral and central target classes, including G-protein coupled receptors, nuclear hormone receptors, enzymes, exchangers, transporters, ion channels, and nucleoside analogs.
Responsible for all discovery chemistry programs in Metabolics Disease, placing 13 drug candidates into development with a team of 60 chemists.
Proactively worked to assure a sustainable pipeline of Metabolics Disease (diabetes/obesity) clinical candidates.
Regularly reviewed and creatively commented upon Metabolics Disease medicinal chemistry programs and actively participated in all discovery working group meetings.
Designated Medicinal Chemistry Division liaison to preclinical ADME, toxicology and pharmaceutics, helping establish processes to enable the timely identification of quality drug candidates.
Established priorities for the efficient application of ADME, toxicology and pharmaceutics resources to the Metabolics Disease program portfolio.
Routinely involved in the scientific assessment of potential external research collaborations and drug candidates.

Executive Director/Vice President Discovery Chemistry, 2001 - 2002

Responsible for all discovery chemistry programs at research site (Cardiovascular and Metabolics Disease), placing four compounds into development while leading a department of 100 chemists.
Regularly reviewed and creatively commented upon Metabolics Disease medicinal chemistry programs and actively participated in all discovery working group meetings.
Established priorities for the efficient application of ADME, toxicology and pharmaceutics resources.

Executive Director Discovery Chemistry, 1999 - 2001

Responsible for all discovery chemistry programs in cardiovascular disease, placing four compounds into development with a department of 50 chemists.

Executive Director Discovery Chemistry, 1998 - 1999

Responsible for all programs in Cardiovascular Disease and Immunology, placing four compounds into development.
Member of Joint Research Committee for Icagen collaboration.

Director Discovery Chemistry, 1993 - 1997

Responsible for several programs in virology, cardiovascular disease, oncology, and immunology.
Discovery team co-leader and first-inventor of entecavir (BaracludeTM), an orally active nucleoside analog with potent efficacy against human hepatitis B virus, currently marketed worldwide.
Led program identifying a lobucavir prodrug that significantly enhanced oral bioavailability.
Devised and helped implement a strategy to ensure exclusive access to bulk quantities of epothilones (oncology) by in-licensing proprietary know-how of fermentation processes.

Director and Associate Director Discovery Chemistry, 1989 - 1993

Responsible for antiviral chemistry efforts targeting herpesviruses, influenza and human immunodeficiency virus (nucleoside/nucleotide analogs, HIV protease, new leads).
Co-leader of the Ras farnesyl transferase program (oncology).

Group Leader Discovery Chemistry, 1986 - 1989

Responsible for antiviral chemistry programs.
Co-inventor of lobucavir (which entered Phase III), an orally bioavailable nucleoside analog with activity against herpes simplex virus, varicella-zoster virus, human cytomegalovirus, HIV and hepetitis B virus.
Co-led program leading to the identification of two additional nucleoside-analog development candidates for the treatment of herpes simplex and varicella-zoster virus infections, respectively.

Research Investigator and Group Leader, 1981 - 1986

Publications and Patents